Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions: MET097 Injection, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Overactive Bladder
Interventions: OnabotulinumtoxinA 100 Units; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Greensboro, North Carolina • Winston-Salem, North Carolina

Conditions: HIV Infections
Interventions: pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 50
States / cities: Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more

Conditions: HCG
Interventions: Human Chorionic Gonadotropin, Placebo, Low calorie diet; Drug · Other
Lead sponsor: Dr. Emma's Corporation; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Colts Neck, New Jersey

Conditions: Tissue Expansion, Implant Based Breast Reconstruction
Interventions: Blossom tissue expander, Standard tissue expansion; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Paraosmia
Interventions: Platelet-rich Plasma (PRP), Saline; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: TAK-676, Carboplatin, 5-FU, Paclitaxel, TAK-676 + Carboplatin, Carboplatin + Paclitaxel, Carboplatin + 5-FU, TAK-676 + Carboplatin + 5-FU, TAK-676 + Carboplatin + Paclitaxel; Drug · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more

Conditions: Cardiovascular Surgery, Pain, Postoperative, Block
Interventions: Liposomal bupivacaine, Normal Saline Flush, 0.9% Injectable Solution_#1; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dehydration, Gastroenteritis
Interventions: multiple electrolyte solution, saline; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 6 Months to 10 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Atlanta, Georgia • Cincinnati, Ohio • Cleveland, Ohio + 3 more

Conditions: Androgenetic Alopecia
Interventions: Autologous Platelet Rich Plasma, Saline solution injection; Device
Lead sponsor: Regen Lab SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Alzheimer Disease, Late Onset
Interventions: Bacillus of Calmette and Guerin (BCG); Biological
Lead sponsor: Mindful Diagnostics and Therapeutics, LLC; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Eau Claire, Wisconsin

Conditions: Painful Diabetic Neuropathies
Interventions: Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline); Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more

Conditions: Smoking Cessation
Interventions: Novolin R; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years to 40 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Apixaban; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Knee Osteoarthritis
Interventions: ACP Max™, Depo-Medrol®; Device
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Knoxville, Tennessee • Danville, Virginia

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more

Conditions: Postoperative Pain
Interventions: HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Bariatric Surgery, Postoperative Nausea and Vomiting
Interventions: Botulinum toxin pyloroplasty, Normal saline pyloric injection; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Migraine
Interventions: lidocaine, bupivicaine and saline, lidocaine plus bupivicaine plus triamcinolone (steroid); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

Blossom® Smart Expander Device for Tissue Expander/Implant-Based Breast Reconstruction

Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

BCG and Plasma Amyloid in Non-Demented Adults

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Neuro Biomarkers of Smoking Behavior

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

BLOCK-SAH - PPF-Block for Post-SAH Headache

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy

A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache